Latest news with #MarinusPharmaceuticals
Associated Press
30-07-2025
- Business
- Associated Press
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Marinus (MRNS) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Marinus between March 17, 2021 and May 7, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) on behalf of long-term stockholders following a class action complaint that was filed against Marinus on June 5, 2024 with a Class Period from March 17, 2021 and May 7, 2024. Our investigation concerns whether the board of directors of Marinus have breached their fiduciary duties to the company. According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. If you are a long-term stockholder of Marinus, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 [email protected]
Yahoo
25-07-2025
- Business
- Yahoo
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best penny stocks under $1 to buy now. On June 25, Ovid Therapeutics announced a definitive agreement with Immedica Pharma AB. Under this agreement, Ovid will sell its future royalty rights related to sales of ganaxolone outside of China for $7 million in cash. In 2024, Ovid recorded ~$566,000 in ganaxolone royalty revenues. This transaction will not impact Ovid's current pipeline, as the company has not been actively developing ganaxolone. The sale of royalty rights to Immedica includes those stemming from an exclusive patent license agreement Ovid entered into with Marinus Pharmaceuticals Inc. in February 2022. A close-up of a medicine bottle, illustrating the efforts in providing adult solid tumor treatment options. Under that prior agreement, Ovid was entitled to receive royalties on ganaxolone sales for CDKL5 deficiency disorder/CDD in the US and Europe. In a related development, Immedica announced the completion of its acquisition of Marinus in February this year. Immedica has also agreed to acquire or license Ovid's global ganaxolone intellectual property/IP portfolio and amend the existing license to cover additional indications. Ovid Therapeutics Inc. (NASDAQ:OVID) is a biopharmaceutical company that develops impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the US. While we acknowledge the potential of OVID as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
15-07-2025
- Health
- Globe and Mail
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Status Epilepticus pipeline constitutes 5+ key companies continuously working towards developing 5+ Status Epilepticus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' Status Epilepticus Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Status Epilepticus Market. The Status Epilepticus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Status Epilepticus Pipeline Report: Companies across the globe are diligently working toward developing novel Status Epilepticus treatment therapies with a considerable amount of success over the years. Status Epilepticus companies working in the treatment market are Marinus Pharmaceuticals, Pfizer, UCB Biopharma, Rafa Laboratories, Sage Therapeutics, and others, are developing therapies for the Status Epilepticus treatment Emerging Status Epilepticus therapies in the different phases of clinical trials are- Ganaxolone, Lorazepam, Staccato alprazolam, Seizalam, SAGE-547, and others are expected to have a significant impact on the Status Epilepticus market in the coming years. In October 2024, Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing novel therapies for seizure disorders, has shared new findings from its pivotal Phase 3 RAISE trial investigating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE). The data were presented at the Neurocritical Care Society (NCS) Annual Meeting. Initial results, released in June 2024, indicated that the trial achieved one of its two co-primary endpoints. Status Epilepticus Overview Status Epilepticus is a medical emergency characterized by a seizure lasting more than 5 minutes or multiple seizures occurring close together without full recovery of consciousness between them. It can affect people with or without a history of epilepsy and may result from brain injury, infection, stroke, or abrupt medication withdrawal. If not treated promptly, it can lead to permanent brain damage, coma, or death. Immediate intervention with anti-seizure medications, often intravenously, is essential to stop the seizures and stabilize the patient. Emerging Status Epilepticus Drugs Under Different Phases of Clinical Development Include: Ganaxolone: Marinus Pharmaceuticals Lorazepam: Pfizer Staccato alprazolam: UCB Biopharma Seizalam: Rafa Laboratories IV Ganaxolone active: Marinus Pharmaceuticals SAGE-547: Sage Therapeutics Status Epilepticus Route of Administration Status Epilepticus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Oral Parenteral Intravenous Subcutaneous Topical Status Epilepticus Molecule Type Status Epilepticus Products have been categorized under various Molecule types, such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Status Epilepticus Pipeline Therapeutics Assessment Status Epilepticus Assessment by Product Type Status Epilepticus By Stage and Product Type Status Epilepticus Assessment by Route of Administration Status Epilepticus By Stage and Route of Administration Status Epilepticus Assessment by Molecule Type Status Epilepticus by Stage and Molecule Type DelveInsight's Status Epilepticus Report covers around 5+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Status Epilepticus product details are provided in the report. Download the Status Epilepticus pipeline report to learn more about the emerging Status Epilepticus therapies Some of the key companies in the Status Epilepticus Therapeutics Market include: Key companies developing therapies for Status Epilepticus are - UCB Biopharma SRL, Pfizer, Marinus Pharmaceuticals, Sage Therapeutics, Shire, and others. Status Epilepticus Pipeline Analysis: The Status Epilepticus pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Status Epilepticus with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Status Epilepticus Treatment. Status Epilepticus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Status Epilepticus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Status Epilepticus market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Status Epilepticus drugs and therapies Status Epilepticus Pipeline Market Drivers Rising epilepsy prevalence, Advancements in drug development, Improved diagnostics & regulatory support, Technological innovation, are some of the important factors that are fueling the Status Epilepticus Market. Status Epilepticus Pipeline Market Barriers However, Limited awareness & access, Adverse effects & safety concerns, High cost & infrastructure needs, Regulatory complexity, and other factors are creating obstacles in the Status Epilepticus Market growth. Scope of Status Epilepticus Pipeline Drug Insight Table of Contents 1. Status Epilepticus Report Introduction 2. Status Epilepticus Executive Summary 3. Status Epilepticus Overview 4. Status Epilepticus- Analytical Perspective In-depth Commercial Assessment 5. Status Epilepticus Pipeline Therapeutics 6. Status Epilepticus Late Stage Products (Phase II/III) 7. Status Epilepticus Mid Stage Products (Phase II) 8. Status Epilepticus Early Stage Products (Phase I) 9. Status Epilepticus Preclinical Stage Products 10. Status Epilepticus Therapeutics Assessment 11. Status Epilepticus Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Status Epilepticus Key Companies 14. Status Epilepticus Key Products 15. Status Epilepticus Unmet Needs 16 . Status Epilepticus Market Drivers and Barriers 17. Status Epilepticus Future Perspectives and Conclusion 18. Status Epilepticus Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
